|By PR Newswire||
|March 13, 2014 06:30 AM EDT||
CALGARY, March 13, 2014 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the year ended December 31, 2014.
"In 2013, we reported data from a number of clinical studies, which included our first data correlating specific biomarkers with survival in NSCLC lung cancer patients and culminated with the reporting of our first randomized data in head and neck cancer," said Dr. Brad Thompson, President and CEO of Oncolytics. "Our randomized clinical program continues to move ahead with six sponsored studies currently enrolling patients in a range of indications. Each of these studies will advance in parallel with our ongoing head and neck program which we are currently in the process of designing a follow-on registration study for discussion with regulators."
Since January 1, 2013, specific highlights announced by the Company include:
Clinical Trial Results
- Top-line data for the endpoints in a double blinded, randomized clinical study examining REOLYSIN® in combination with carboplatin and paclitaxel in patients with second-line platinum-refractory, taxane-naïve head and neck cancers (REO 018). An analysis was performed on an intent-to-treat basis of 118 patients with loco-regional head and neck cancer, with or without metastases. Patients in the control arm were treated with carboplatin and paclitaxel, while patients in the test arm were treated with carboplatin, paclitaxel and REOLYSIN. The analysis showed a median progression free survival (PFS) of 94 days (13.4 weeks) in the test arm (n=62), versus 50 days (7.1 weeks) in the control arm (n=56). The test arm maintained a PFS benefit over the control arm through five cycles of therapy. An analysis of 88 loco-regional patients that did not receive additional therapy following discontinuation of study treatment showed a median overall survival (OS) of 150 days (21.4 weeks) in the test arm (n=50), versus 115 days (16.4 weeks) in the control arm (n=38). REOLYSIN was deemed safe and well-tolerated by patients. The side effects experienced by patients in the test arm of the study were consistent with expectations based on outcomes of earlier clinical studies using REOLYSIN. Patients on the test arm of the study experienced a higher incidence of flu-like symptoms consistent with treatment with a virus, most commonly mild fever, chills, nausea and diarrhea, on both a per-patient and a per-cycle basis. Fewer patients required dose reductions of paclitaxel due to neuropathy or neurotoxicity on the test arm than the control arm (zero in the test arm versus six in the control arm; p=0.028). On this basis, the Company intends to explore the potential chemoprotective and neuroprotective properties of REOLYSIN in future clinical studies;
- Positive final results from a U.S. Phase 2 study examining the use of REOLYSIN in combination with carboplatin and paclitaxel in patients with stage IV non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumors (REO 016). Response evaluation for 36 evaluable patients showed 11 partial responses (PR) (30%) (EGFR amplified, five; BRAF two; Kras, three; EGFR mutated, one), 21 stable disease (SD), and four progressive disease (PD). The data also correlated a number of molecular abnormalities with best response, PFS and one-year survival. Current data in these patients demonstrates that 20 of 36 evaluable patients (56%) survived a year or more. There were 13 patients with only EGFR mutations or amplifications, of whom nine (69.2%) survived a year or longer. Four of four (100%) patients with BRAF and EGFR amplification survived a year or longer;
- Final tumor response and PFS data from a U.S. Phase 2 clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel (REO 021). Of the 25 evaluable patients who had more than one cycle of therapy, 23 (92%) exhibited overall tumor shrinkage. When evaluated for best response, which is the best percentage response recorded on study compared to baseline, 10 patients (40%) had PR, while a further 14 (56%) showed SD, and one (4%), had PD. Using RECIST criteria to evaluate best overall response, 10 patients (40%) had PRs, 12 (48%) showed SD and three (12%), had PD. 31.8% of patients with sufficient follow up had a PFS greater than six months;
- Reaching the stage 1 endpoint in a U.S. Phase 2 clinical trial in patients with metastatic melanoma (REO 020) after only 14 patients were enrolled. The primary objective of this Phase 2 trial was to assess the antitumor effect of the treatment regimen in the study population in terms of objective response rates. The secondary objectives were to assess progression-free survival and overall survival for the treatment regimen; the disease control rate (complete response (CR) plus PR plus SD) and duration, and to assess the safety and tolerability of the treatment regimen in the study population. Three of the 14 patients exhibited a PR, and an additional seven patients had SD for a disease control rate of 71.5%; and
Positive preliminary results from a Phase 1 study examining the
intravenous administration of REOLYSIN in combination with FOLFIRI in
patients with metastatic colorectal cancer (REO 022) in a poster
presentation at the ASCO Gastrointestinal Cancers Symposium. Of the 18
patients evaluable for response there was one PR and nine had SD. The
combined overall PFS of FOLFIRI-naïve and FOLFIRI-failed patients was
7.4 months. The authors concluded that the combination of REOLYSIN and
FOLFIRI was safe and well tolerated and resulted in disease control in
the majority of evaluable patients, including patients that had
previously progressed on Irinotecan.
- At December 31, 2013 the Company reported $27.2 million in cash, cash equivalents and short-term investments; and
- Subsequent to year end, entry into a share purchase agreement with Lincoln Park Capital Fund, LLC that will provide an initial investment in Oncolytics of US$1.0 million and make available additional periodic investments of up to US$25.0 million over a 30-month term.
|ONCOLYTICS BIOTECH INC.|
|CONSOLIDATED STATEMENTS OF FINANCIAL POSITION|
|Cash and cash equivalents||25,220,328||19,323,541|
|Total current assets||27,689,568||21,668,842|
|Property and equipment||532,459||409,248|
|Total non-current assets||532,459||409,248|
|Liabilities And Shareholders' Equity|
|Accounts payable and accrued liabilities||6,008,661||7,291,310|
|Total current liabilities||6,008,661||7,291,310|
|Issued: December 31, 2013 - 84,803,818|
|December 31, 2012 - 76,710,285||228,612,564||198,155,091|
|Accumulated other comprehensive loss||79,698||(57,115)|
|Total shareholders' equity||22,213,366||14,786,780|
|Total liabilities and equity||28,222,027||22,078,090|
|ONCOLYTICS BIOTECH INC.|
|CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS|
|For the years ending December 31,||
|Research and development||18,506,064||31,402,625||23,386,685|
|Loss before the following||(23,898,724)||(36,688,050)||(28,721,267)|
|Write down of asset available for sale||—||—||(735,681)|
|Change in fair value of warrant liability||—||—||36,000|
|Loss before income taxes||(23,527,239)||(36,343,047)||(29,004,701)|
|Income tax expense||(5,408)||(30,474)||(40,000)|
Other comprehensive income items that may
be reclassified to net loss
|Net comprehensive loss||(23,395,834)||(36,313,135)||(29,005,542)|
|Basic and diluted loss per common share||(0.28)||(0.48)||(0.41)|
|Weighted average number of shares (basic and diluted)||83,530,981||76,102,062||70,911,526|
|ONCOLYTICS BIOTECH INC.|
|CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY|
|As at December 31, 2010||155,439,610||4,108,652||19,399,489||(156,660)||(142,396,131)||36,394,960|
|Net loss and comprehensive income||—||—||—||39,159||(29,044,701)||(29,005,542)|
|Exercise of warrants||21,487,080||(1,455,025)||—||—||—||20,032,055|
|Exercise of stock options||355,876||—||(62,473)||—||—||293,403|
|Share based compensation||—||—||1,805,503||—||—||1,805,503|
|As at December 31, 2011||177,282,566||2,653,627||21,142,519||(117,501)||(171,440,832)||29,520,379|
|Net loss and comprehensive income||—||—||—||60,386||(36,373,521)||(36,313,135)|
|Issued, pursuant to a bought deal financing||19,386,903||376,892||—||—||—||19,763,795|
|Expiry of warrants||—||(2,653,627)||2,653,627||—||—||—|
|Exercise of stock options||1,485,622||—||(400,632)||—||—||1,084,990|
|Share based compensation||—||—||730,751||—||—||730,751|
|As at December 31, 2012||198,155,091||376,892||24,126,265||(57,115)||(207,814,353)||14,786,780|
|Net loss and comprehensive income||—||—||—||136,813||(23,532,647)||(23,395,834)|
|Issued, pursuant to a bought deal financing||30,218,796||—||—||—||—||30,218,796|
|Expiry of warrants||—||—||—||—||—||—|
|Exercise of stock options||238,677||—||(59,437)||—||—||179,240|
|Share based compensation||—||—||424,384||—||—||424,384|
|As at December 31, 2013||228,612,564||376,892||24,491,212||79,698||(231,347,000)||22,213,366|
|ONCOLYTICS BIOTECH INC.|
|CONSOLIDATED STATEMENTS OF CASH FLOWS|
|For the years ending December 31,||
|Net loss for the year||(23,532,647)||(36,373,521)||(29,044,701)|
|Amortization - property and equipment||131,623||109,275||92,590|
|Share based compensation||424,384||730,751||1,805,503|
|Change in fair value of warrant liability||—||—||(36,000)|
|Write down of asset available for sale||—||—||735,681|
|Unrealized foreign exchange loss||(89,721)||89,890||115,234|
|Net change in non-cash working capital||(1,374,172)||1,187,967||3,790,510|
|Cash used in operating activities||(24,440,533)||(34,255,638)||(22,541,183)|
|Acquisition of property and equipment||(254,834)||(126,412)||(257,790)|
|Redemption (purchase) of short-term investments||(32,416)||(32,441)||1,672,459|
|Cash provided by (used in) investing activities||(287,250)||(158,853)||1,414,669|
|Proceeds from exercise of stock options and warrants||179,240||1,084,990||14,824,658|
|Proceeds from public offering||30,218,796||19,763,795||—|
|Cash provided by financing activities||30,398,036||20,848,785||14,824,658|
|Increase (decrease) in cash||5,670,253||(13,565,706)||(6,301,856)|
|Cash and cash equivalents, beginning of year||19,323,541||32,918,751||39,296,682|
|Impact of foreign exchange on cash and cash equivalents||226,534||(29,504)||(76,075)|
|Cash and cash equivalents, end of year||25,220,328||19,323,541||32,918,751|
To view the Company's Fiscal 2013 Consolidated Financial Statements, related Notes to Consolidated Financial Statements, and Management's Discussion and Analysis, please see the Company's annual filings which will be available on www.sedar.com and on www.oncolyticsbiotech.com/for-investors/financials.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's belief as to the potential of REOLYSIN as a cancer therapeutic; the Company's expectations as to the success of its research and development programs in 2014 and beyond, the Company's planned operations, the value of the additional patents and intellectual property; the Company's expectations related to the applications of the patented technology; the Company's expectations as to adequacy of its existing capital resources; the design, timing, success of planned clinical trial programs; and other statements related to anticipated developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.
In their session at 17th Cloud Expo, Hal Schwartz, CEO of Secure Infrastructure & Services (SIAS), and Chuck Paolillo, CTO of Secure Infrastructure & Services (SIAS), provide a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. In his role as CEO of Secure Infrastructure & Services (SIAS), Hal Schwartz provides leadership and direction for the company.
Jul. 31, 2015 11:45 AM EDT Reads: 117
In a recent research, analyst firm IDC found that the average cost of a critical application failure is $500,000 to $1 million per hour and the average total cost of unplanned application downtime is $1.25 billion to $2.5 billion per year for Fortune 1000 companies. In addition to the findings on the cost of the downtime, the research also highlighted best practices for development, testing, application support, infrastructure, and operations teams.
Jul. 31, 2015 11:45 AM EDT Reads: 113
Mobile, social, Big Data, and cloud have fundamentally changed the way we live. “Anytime, anywhere” access to data and information is no longer a luxury; it’s a requirement, in both our personal and professional lives. For IT organizations, this means pressure has never been greater to deliver meaningful services to the business and customers.
Jul. 31, 2015 10:50 AM EDT
Puppet Labs has announced the next major update to its flagship product: Puppet Enterprise 2015.2. This release includes new features providing DevOps teams with clarity, simplicity and additional management capabilities, including an all-new user interface, an interactive graph for visualizing infrastructure code, a new unified agent and broader infrastructure support.
Jul. 31, 2015 10:00 AM EDT Reads: 140
For IoT to grow as quickly as analyst firms’ project, a lot is going to fall on developers to quickly bring applications to market. But the lack of a standard development platform threatens to slow growth and make application development more time consuming and costly, much like we’ve seen in the mobile space. In his session at @ThingsExpo, Mike Weiner, Product Manager of the Omega DevCloud with KORE Telematics Inc., discussed the evolving requirements for developers as IoT matures and conducte...
Jul. 31, 2015 08:45 AM EDT Reads: 301
Container technology is sending shock waves through the world of cloud computing. Heralded as the 'next big thing,' containers provide software owners a consistent way to package their software and dependencies while infrastructure operators benefit from a standard way to deploy and run them. Containers present new challenges for tracking usage due to their dynamic nature. They can also be deployed to bare metal, virtual machines and various cloud platforms. How do software owners track the usag...
Jul. 31, 2015 08:00 AM EDT Reads: 158
Explosive growth in connected devices. Enormous amounts of data for collection and analysis. Critical use of data for split-second decision making and actionable information. All three are factors in making the Internet of Things a reality. Yet, any one factor would have an IT organization pondering its infrastructure strategy. How should your organization enhance its IT framework to enable an Internet of Things implementation? In his session at @ThingsExpo, James Kirkland, Red Hat's Chief Arch...
Jul. 30, 2015 07:30 PM EDT Reads: 1,398
Providing the needed data for application development and testing is a huge headache for most organizations. The problems are often the same across companies - speed, quality, cost, and control. Provisioning data can take days or weeks, every time a refresh is required. Using dummy data leads to quality problems. Creating physical copies of large data sets and sending them to distributed teams of developers eats up expensive storage and bandwidth resources. And, all of these copies proliferating...
Jul. 30, 2015 06:30 PM EDT Reads: 889
Malicious agents are moving faster than the speed of business. Even more worrisome, most companies are relying on legacy approaches to security that are no longer capable of meeting current threats. In the modern cloud, threat diversity is rapidly expanding, necessitating more sophisticated security protocols than those used in the past or in desktop environments. Yet companies are falling for cloud security myths that were truths at one time but have evolved out of existence.
Jul. 30, 2015 06:00 PM EDT Reads: 1,803
Digital Transformation is the ultimate goal of cloud computing and related initiatives. The phrase is certainly not a precise one, and as subject to hand-waving and distortion as any high-falutin' terminology in the world of information technology. Yet it is an excellent choice of words to describe what enterprise IT—and by extension, organizations in general—should be working to achieve. Digital Transformation means: handling all the data types being found and created in the organizat...
Jul. 30, 2015 05:00 PM EDT Reads: 1,089
Public Cloud IaaS started its life in the developer and startup communities and has grown rapidly to a $20B+ industry, but it still pales in comparison to how much is spent worldwide on IT: $3.6 trillion. In fact, there are 8.6 million data centers worldwide, the reality is many small and medium sized business have server closets and colocation footprints filled with servers and storage gear. While on-premise environment virtualization may have peaked at 75%, the Public Cloud has lagged in adop...
Jul. 30, 2015 04:00 PM EDT Reads: 2,204
SYS-CON Events announced today that HPM Networks will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. For 20 years, HPM Networks has been integrating technology solutions that solve complex business challenges. HPM Networks has designed solutions for both SMB and enterprise customers throughout the San Francisco Bay Area.
Jul. 30, 2015 03:45 PM EDT Reads: 450
The time is ripe for high speed resilient software defined storage solutions with unlimited scalability. ISS has been working with the leading open source projects and developed a commercial high performance solution that is able to grow forever without performance limitations. In his session at Cloud Expo, Alex Gorbachev, President of Intelligent Systems Services Inc., shared foundation principles of Ceph architecture, as well as the design to deliver this storage to traditional SAN storage co...
Jul. 30, 2015 03:00 PM EDT Reads: 1,741
The Software Defined Data Center (SDDC), which enables organizations to seamlessly run in a hybrid cloud model (public + private cloud), is here to stay. IDC estimates that the software-defined networking market will be valued at $3.7 billion by 2016. Security is a key component and benefit of the SDDC, and offers an opportunity to build security 'from the ground up' and weave it into the environment from day one. In his session at 16th Cloud Expo, Reuven Harrison, CTO and Co-Founder of Tufin,...
Jul. 30, 2015 03:00 PM EDT Reads: 487
MuleSoft has announced the findings of its 2015 Connectivity Benchmark Report on the adoption and business impact of APIs. The findings suggest traditional businesses are quickly evolving into "composable enterprises" built out of hundreds of connected software services, applications and devices. Most are embracing the Internet of Things (IoT) and microservices technologies like Docker. A majority are integrating wearables, like smart watches, and more than half plan to generate revenue with ...
Jul. 30, 2015 02:30 PM EDT Reads: 101